# HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection

> **NCT02309918** · PHASE2 · COMPLETED · sponsor: **HepNet Study House, German Liverfoundation** · enrollment: 20 (actual)

## Conditions studied

- Acute Hepatitis C

## Interventions

- **DRUG:** LDV/SOF FDC

## Key facts

- **NCT ID:** NCT02309918
- **Lead sponsor:** HepNet Study House, German Liverfoundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309918, "HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02309918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*